William Hoffman Sells 200,000 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock

Inari Medical, Inc. (NASDAQ:NARIGet Free Report) Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the transaction, the director now owns 238,987 shares in the company, valued at approximately $14,451,543.89. This represents a 45.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

William Hoffman also recently made the following trade(s):

  • On Monday, December 16th, William Hoffman sold 60,000 shares of Inari Medical stock. The stock was sold at an average price of $55.66, for a total value of $3,339,600.00.
  • On Monday, November 18th, William Hoffman sold 60,000 shares of Inari Medical stock. The shares were sold at an average price of $51.16, for a total value of $3,069,600.00.
  • On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00.
  • On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00.

Inari Medical Stock Down 0.2 %

Shares of NASDAQ:NARI traded down $0.15 during midday trading on Wednesday, hitting $79.30. The stock had a trading volume of 11,583,187 shares, compared to its average volume of 10,312,277. The company has a market cap of $4.64 billion, a P/E ratio of -58.74 and a beta of 0.97. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.69. The business’s 50-day simple moving average is $52.85 and its 200-day simple moving average is $48.92.

Analyst Upgrades and Downgrades

NARI has been the topic of several research reports. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a research report on Tuesday. Baird R W lowered Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Robert W. Baird reiterated a “neutral” rating and set a $80.00 price objective (down from $81.00) on shares of Inari Medical in a report on Tuesday. Canaccord Genuity Group restated a “hold” rating and issued a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday. Finally, Oppenheimer started coverage on Inari Medical in a research report on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price target for the company. Twelve equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $68.00.

Check Out Our Latest Research Report on NARI

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of NARI. Jennison Associates LLC raised its stake in Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock valued at $65,021,000 after acquiring an additional 610,468 shares during the period. Vestal Point Capital LP increased its holdings in shares of Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock valued at $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after purchasing an additional 786,691 shares during the period. Armistice Capital LLC lifted its stake in shares of Inari Medical by 353.1% during the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock worth $48,595,000 after buying an additional 786,501 shares during the last quarter. Finally, Bamco Inc. NY boosted its holdings in shares of Inari Medical by 29.5% during the 3rd quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock worth $41,493,000 after buying an additional 228,977 shares during the period. Institutional investors own 90.98% of the company’s stock.

About Inari Medical

(Get Free Report)

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.

Further Reading

Insider Buying and Selling by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.